<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify"><strong>Did you buy IBRX securities between </strong><strong>January 19, 2026, and March 24, 2026?</strong></p> <p align="justify"><strong>Affected IBRX Investor Summary</strong></p> <ul type="disc"> <li style="text-align:justify;"><strong>Who:</strong> ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/IBRX" rel="nofollow">IBRX</a>)</li> <li style="text-align:justify;"><strong>What:</strong> Securities fraud class action lawsuit filed</li> <li style="text-align:justify;"><strong>Class Period:</strong> January 19, 2026 through March 24, 2026</li> <li style="text-align:justify;"><strong>Deadline to Seek Lead Plaintiff Status:</strong> May 26, 2026</li> <li style="text-align:justify;"><strong>Key Lawsuit Allegations:</strong> Material misstatements and/or omissions concerning the company's lead biologic product, Anktiva.</li> <li style="text-align:justify;"><strong>Investor Action: </strong>Contact <a href="https://www.ktmc.com/ibrx-immunitybio-inc-class-action-lawsuit?utm_source=Globe&utm_medium=pressrelease&utm_campaign=ibrx&mktm=PR" rel="nofollow" target="_blank" rel="nofollow">Kessler Topaz Meltzer & Check, LLP (www.ktmc.com</a>) for recovery options</li> </ul> <p align="justify">RADNOR, Pa., April 12, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (<a href="https://www.globenewswire.com/Tracker?data=7hmEWmwmrsZu7HHTI2Xsre0R_x-HPVvEH_l0qvzLHM94GWSvylfkto76-4yR4y9sIME_glHh2VIcJ7d9yM3RSg==" rel="nofollow" target="_blank" rel="nofollow">www.ktmc.com</a>), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against ImmunityBio, Inc. (ImmunityBio) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/IBRX" rel="nofollow">IBRX</a>) on behalf of those who purchased or acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, inclusive. The lawsuit is filed in the United States District Court for the Central District of California and is captioned <em>Douglas v. ImmunityBio, Inc., </em>Case No. 2:26-cv-03261 (C.D. Cal.). <strong>Investors have until May 26, 2026, to file for lead plaintiff status.</strong> </p> <p><strong><u>CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: </u></strong><br />If you purchased or acquired ImmunityBio securities and have lost money on your investment, you are encouraged to contact KTMC attorney Jonathan Naji, Esq. at:</p> <p>(484) 270-1453<br /> [email protected] <br /><a href="https://www.globenewswire.com/Tracker?data=EXuq8zoHsS_YyXQKuwXGNTLMPTi7mNL694yc87dEEPnGqLt5CxG5axZ5KVXFthmNJKg9AtC9ry-gUITAvkgiZmw0dKrn9WaKyb7doEtGqj-lEzNYv9be-3_wwMnWf2th9n6EtPh6Ti3ndHyAQe5TdEtSmFqnzmeyrznFlf7ht-blUEa1MZzLUFR3XcctflXx6igcMMocO1IDD9p9nyxGJSmoKnelO0X3udRjZB23d2awzJGpIqdPerUSLvlkeR-ai2rcpvxqmag_cvFAd5vmE-uZfe9EHl0OBnd2Ef16vwhq931IL_07FCrKGfLo7MSWYG00K-s0HiiF91RVFyR7C0A29EuAAh7qnqpvMbws8Ld0qZ2zOARpO_wSZBKUr53Wd0TaGyPhqRY7A9n8vbVVeg==" rel="nofollow" target="_blank" rel="nofollow">https://www.ktmc.com/ibrx-immunitybio-inc-class-action-lawsuit?utm_source=Globe&utm_medium=pressrelease&utm_campaign=ibrx&mktm=PR</a></p> <p align="justify">There is no cost or obligation to speak with an attorney.</p> <p><strong>Learn more about ImmunityBio, Inc. on YouTube:</strong></p> <ul> <li><a href="https://www.youtube.com/watch?v=Bzj-LEElKn8" rel="nofollow" target="_blank" rel="nofollow"><strong>ImmunityBio, Inc. Securities Class Action Lawsuit (long video)</strong></a></li> <li><a href="https://www.youtube.com/shorts/CVXV4L8D6LA" rel="nofollow" target="_blank" rel="nofollow"><strong>ImmunityBio, Inc. Securities Class Action Lawsuit (short video)</strong></a></li> </ul> <p align="justify"><strong><u>IMMUNITYBIO, INC.</u></strong> <strong><u>CLASS ACTION LAWSUIT - COMPLAINT ...</u></strong></p><p><a href=https://www.benzinga.com/pressreleases/26/04/g51771069/immunitybio-inc-ibrx-investors-may-26-2026-filing-deadline-in-securities-fraud-class-action-contac?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel alt=ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP>Full story available on Benzinga.com</a></p>
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
